Tagged with CNS

Opinion In the third of a series of articles chronicling Biogen/Eisai’s Alzheimer’s Disease (AD) treatment aducanumab’s torturous journey to market, Dr Neil Cashman highlights what the next steps in the process will be, why US FDA approval for the drug will pave the way for researchers working on second-generation AD medicines,…

USA Ivan Cheung, head of Japanese firm Eisai’s US operations, highlights the significance of a potential 2021 US FDA approval for Alzheimer’s Disease drug aducanumab, developed in collaboration with Biogen. Cheung also compares the differing challenges of the oncology and neuroscience markets and outlines the unique Eisai company culture.   We…

Opinion Holmusk’s Nawal Roy outlines why a cure for Alzheimer’s Disease is the “Holy Grail” of medicine today, the reasons for so many biotech companies failing to develop effective treatments for the disease, and why a more holistic systems approach may be the key to future success.   The ingenuity of…

USA PharmaBoardroom recently spoke to CNS-focused Danish biopharma company Lundbeck’s EVP and Head of North America Peter Anastasiou, who highlighted the long-term damage COVID-19 is causing to the general mental health of society, and how Lundbeck is well-positioned to address this in North America.   As the global pandemic rages on,…

USA Industry veteran Peter Anastasiou, executive VP and head of North America for Danish CNS specialist Lundbeck, outlines the performance of Lundbeck’s specialty portfolio in the US market, the challenges of working in the CNS space, and how the company is adapting to the problems posed by the COVID-19 pandemic.  …

Mexico Biogen Mexico’s Luis Calderon discusses establishing the affiliate, the opportunities apparent in the Mexican neurodegenerative disease market, and the impact of the country’s ongoing health reforms.   In my experience, companies dedicated to particular therapeutic areas seem to be able to learn faster compared to companies with broader portfolios Luis,…

Mexico UCB’s Omar Lugo Aguirre outlines the company’s response to the COVID-19 pandemic in Mexico, countering stigmas around neurodegenerative and mental diseases, and the abundant opportunities that Mexico and the region carries for the firm.   The upcoming three years are crucial and UCB Mexico wants to play a role elevating…

Mexico Sara Montero, managing director of Lundbeck Mexico, Central America and Andean countries since January 2020, explains her key priorities and the importance of the region for Lundbeck, highlights the current situation for mental illness in Latin America (LatAm) and outlines her objective to bring innovative treatments to Mexican patients.  …

China Dr Li Shuai of pain- and CNS-focused Chinese biotech SIMR outlines the history of the company, the unmet medical needs it is seeking to address, its partnership strategy, and the complexities of attracting and retaining talent in the highly competitive Chinese market.   In 2014, my first angel investor actually…

Sweden BioArctic is a Swedish biopharma company with the vision to become a world-leader in the research and development of disease-modifying treatments for patients with neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’s disease, and pioneering treatment methods for complete spinal cord injuries. Gunilla Osswald, CEO, explains how BioArctic is uniquely…

Sweden Swedish biotech BioArctic, in collaboration with Japanese firm Eisai, has seen positive Phase IIb results for its BAN2401 antibody – potentially the first disease-modifying treatment for Alzheimer’s Disease and the next global blockbuster.   The results from the Phase IIb study strengthen BioArctic’s belief that BAN2401’s unique binding profile is…

Alzheimer's Alzheimer’s drugs represent a high-risk, high-reward proposition for global pharma. As David H. Crean recently wrote for PharmaBoardroom, “Except for one good piece of news in 2014 — for a dementia drug, Namzaric — there’s nothing by way of an FDA approval going back to 2002, 17 years of failure…